Sylatron 2016 U.S. Promotional Audit Report

Sylatron 2016 U.S. Promotional Audit Report

  • July 2017 •
  • 21 pages •
  • Report ID: 5210658 •
  • Format: PDF
The 5 Key Questions Addressed by this Report:
• How many physicians were reached by Sylatron through personal promotion in 2016 and how does this compare to its peer set in the Melanoma markets?
• What promotional mix was leveraged (e.g., sales rep detailing, physician education, and paid speaking) and what was the median spend on each type of activity?
• How does Merck’s depth of coverage vary within key specialties (e.g., Hematology/Oncology, Medical Oncology, and Internal Medicine) and how does this compare to its peers and the overall set of rep-accessible physicians?
• How often are physicians receiving paid meals for Sylatron throughout the year (e.g., monthly, quarterly, annually)?
• Who were the most detailed prescribers and top paid speakers for Sylatron in 2016?

Data Sources and Methodology:
• MDDetails leverages company-reported financial transaction data disclosed through CMS Open Payments. This data set captures all transfers of value (e.g., speaking fees, consulting fees, travel, education, and meals) made on behalf of a drug or device manufacturer to a physician. Currently, 42 months of longitudinal data is available – covering payments to more than 900,000 U.S. healthcare professionals.
• Over 1,100 paid interactions across 700 physicians made on behalf of Sylatron were carefully examined to support our analysis. In addition, interaction data from 8 peer products (e.g. Cotellic, Imlygic, Intron A, Keytruda, Mekinist, Opdivo, Tafinlar, and Zelboraf ) was leveraged to provide benchmarking and market insights.